v2.3.0.11
Legal Proceedings and Contingencies Narrative (Detail) (USD $)
In Millions, unless otherwise specified
 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended
Jul. 03, 2011
Jul. 04, 2010
Jul. 03, 2011
Jul. 04, 2010
Jul. 03, 2011
Hormone Replacement Therapy [Member]
Dec. 31, 2005
Pending or Threatened Litigation [Member]
March 2005 proposed settlement [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Mar. 31, 2005
Pending or Threatened Litigation [Member]
March 2005 proposed settlement [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Sep. 26, 2004
Pending or Threatened Litigation [Member]
March 2005 proposed settlement [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Jul. 03, 2011
Pending or Threatened Litigation [Member]
Court settlement rejection and Pfizer motion to appeal [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Dec. 31, 2010
Pending or Threatened Litigation [Member]
Court settlement rejection and Pfizer motion to appeal [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Mar. 31, 2011
Pending or Threatened Litigation [Member]
March 2011 proposed settlement [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Jul. 03, 2011
Pending or Threatened Litigation [Member]
March 2011 proposed settlement [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Aug. 31, 2004
Pending or Threatened Litigation [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Jul. 03, 2011
Pending or Threatened Litigation [Member]
Quigley Co, Inc., a wholly owned subsidiary [Member]
Dec. 31, 2010
Pending or Threatened Litigation [Member]
American Optical Corp subsidiary of Warner-Lambert [Member]
Jul. 03, 2011
Pending or Threatened Litigation [Member]
Pfizer - Neurontin Product [Member]
Jan. 31, 2011
Pending or Threatened Litigation [Member]
Pfizer - Neurontin Product [Member]
Nov. 30, 2010
Pending or Threatened Litigation [Member]
Pfizer - Neurontin Product [Member]
Dec. 31, 2008
Pending or Threatened Litigation [Member]
Pharmacia - Average Wholesale Price Litigation [Member]
Jul. 31, 2009
Pending or Threatened Litigation [Member]
IREF -Trade Secrets Action [Member]
Dec. 31, 2008
Pending or Threatened Litigation [Member]
IREF -Trade Secrets Action [Member]
Product Liability Contingency [Line Items]                                          
Product litigation charge, pre-tax $ (14) [1] $ 37 [1] $ 487 [1] $ 174 [1]       $ 369   $ 1,300                      
Product litigation charge, after-tax               229   800                      
Notice of appeal and related motion                 October 2010                        
Number of Ad Hoc Committee claimants agreeing to the company's proposed settlement offer                     40,000                    
Percentage of claimants' vote received on the proposed bankruptcy reorganization of the defendant entity             75.00%                            
Number of defendants                                     11    
Percentage of claimants that agreed to 2004 proposed settlement             80.00%                            
Gross settlement amount offered             430                       125    
Claims payment amount for qualified claimants, first or only payment           215           500                  
Claims payment amount for qualified claimants, second payment                       300                  
Claims installment, payment terms                       Following the earlier of the effective date of a revised plan of reorganization and April 6, 2013                  
Agreed-upon payment amount of plaintiff's legal fees and expenses                       19                  
Agreed upon amount of assets (cash and non-cash) to be contributed to a special purpose trust created to pay claimants, if Quigley's proposed reorganization plan is approved by the court                       550                  
Insurance settlement, gross recovery                         405                
Insurance settlement collection period, in years                           10              
Number of claims seeking damages                             88,000            
Litigation settlement expense         250                                
Cumulative product liability charges in prior years         300                                
Estimated minimum cost to resolve outstanding actions         280                                
Cumulative percentage of actions settled         41.00%                                
Damages awarded by the court                                 47.4 65.4     38.7
Treble damages amount awarded, under appeal                                 $ 142.2        
Actions being taken by Pfizer                               In August 2011, Pfizer appealed the District Court's judgment to the US Court of Appeals       The court has granted Pfizer's motion for a new trial and vacated the jury verdict  
[1] In the first six months of 2011, primarily relates to charges for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies).